<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00295802</url>
  </required_header>
  <id_info>
    <org_study_id>G050103</org_study_id>
    <nct_id>NCT00295802</nct_id>
  </id_info>
  <brief_title>Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer</brief_title>
  <official_title>Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EDAP TMS S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EDAP TMS S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the substantial equivalence of the Ablatherm high&#xD;
      intensity focused ultrasound (HIFU) as compared to cryotherapy for the treatment of low risk,&#xD;
      localized prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary hypothesis of this clinical investigation is that HIFU with the Ablatherm Integrated&#xD;
      Imaging is non-inferior to minimally invasive cryosurgery as an effective treatment method&#xD;
      for low risk, localized prostate cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2006</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Attainment achievement of prostate-specific antigen (PSA) nadir &lt; 0.5 ng/ml and stability of PSA according to American Society for Therapeutic Radiology and Oncology (ASTRO) criteria through 24 month follow up without a positive biopsy</measure>
    <time_frame>Through 24 month period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Achievement of a nadir PSA within 6 months &lt; 0.5 ng/ml</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival, defined as time to death due to any cause</measure>
    <time_frame>From date of treatment until the date of death due to any cause</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease specific survival, defined as the time to death due to the underlying disease</measure>
    <time_frame>&quot;From date of treatment until the date of death due to the underlying cause</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the University of California, Los Angeles Quality of Life (UCLA QOL)</measure>
    <time_frame>1 month, 6 months, 12 months, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the International Prostate Symptom Score (IPSS)</measure>
    <time_frame>1 month, 6 months, 12 months, 24 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>The occurrence of adverse events and device-related adverse events reported</measure>
    <time_frame>through out study</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">141</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>HIFU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Integrated Imaging High Intensity Focused Ultrasound using the Ablatherm Device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cryotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Endocare CRYOcare Cryosurgical and Galil Medical CRYO-HIT Systems (cryotherapy)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Integrated Imaging High Intensity Focused Ultrasound</intervention_name>
    <arm_group_label>HIFU</arm_group_label>
    <other_name>HIFU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endocare CRYOcare Cryosurgical and Galil Medical CRYO-HIT Systems (cryotherapy)</intervention_name>
    <description>Cryotherapy</description>
    <arm_group_label>Cryotherapy</arm_group_label>
    <other_name>Endocare CRYOcare Cryosurgical</other_name>
    <other_name>Galil Medical CRYO-HIT Systems (cryotherapy)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of prostate cancer confirmed by PSA and prostate biopsy&#xD;
&#xD;
          -  Male subjects, aged equal to or over 50 years&#xD;
&#xD;
          -  Organ-confined prostate cancer, clinical stage T1a, b, or c or T2a&#xD;
&#xD;
          -  At least one positive biopsy within the previous 6 months&#xD;
&#xD;
          -  PSA equal to or less than 10 ng/ml&#xD;
&#xD;
          -  Gleason score equal to or less than 6&#xD;
&#xD;
          -  Histological grading of 3+3, 3+2, 2+3, 2+4, or 2+2 based upon the baseline transrectal&#xD;
             ultrasound (TRUS)-guided 10 core biopsy results. A subject with a histological grading&#xD;
             of primary 4 will not be permitted for study enrollment.&#xD;
&#xD;
          -  Prostate volume equal to or less than 40 cc&#xD;
&#xD;
          -  Prostate anteroposterior (AP) diameter equal to or less than 25 mm&#xD;
&#xD;
          -  Normal rectal anatomy and rectal mucosa&#xD;
&#xD;
          -  Maximum rectal wall measurement 6 mm&#xD;
&#xD;
          -  The Investigator has completed a medical history and a physical examination to assure&#xD;
             that the subjects meet all study enrollment criteria&#xD;
&#xD;
          -  The subject is willing and able to read, understand, and sign the study specific&#xD;
             informed consent form&#xD;
&#xD;
          -  The subject agrees to comply with study protocol requirements, including HIFU or&#xD;
             cryotherapy treatment and all follow up visit requirements through 24 months of follow&#xD;
             up treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of seminal vesicle involvement&#xD;
&#xD;
          -  Evidence of lymph node involvement or metastasis&#xD;
&#xD;
          -  Any previous treatment for prostate cancer including: external beam radiation therapy&#xD;
             (EBRT), hormone therapy and/or previous bilateral orchiectomy&#xD;
&#xD;
          -  Previous surgery or procedure of the prostate (except prostate biopsy) or urethra&#xD;
             within the prior one year&#xD;
&#xD;
          -  Calcification inducing a shadow in the prostate which cannot be included in the&#xD;
             targeted volume&#xD;
&#xD;
          -  Large median lobe of the prostate which cannot be included in the target volume&#xD;
&#xD;
          -  Use within the previous 2 months of finasteride&#xD;
&#xD;
          -  Previous rectal surgery (other than hemorrhoidectomy) or history of rectal disease&#xD;
&#xD;
          -  Active inflammatory bowel syndrome&#xD;
&#xD;
          -  Current superficial bladder cancer, urethral stricture, or bladder neck contracture&#xD;
&#xD;
          -  Active urinary tract infection or prostatitis (the subject may be enrolled once the&#xD;
             infection has been treated and has resolved)&#xD;
&#xD;
          -  Compromised renal function or upper urinary tract disease as a result of urinary&#xD;
             obstruction&#xD;
&#xD;
          -  A history of bleeding disorders/coagulopathy or ongoing treatment for this condition&#xD;
&#xD;
          -  Urinary tract or rectal fistula&#xD;
&#xD;
          -  Rectal fibrosis, rectal stenosis, or other anomalies making the Ablatherm Integrated&#xD;
             Imaging rectal probe insertion difficult&#xD;
&#xD;
          -  Anatomical anomaly of the rectum or anomaly of the rectal mucous membrane&#xD;
&#xD;
          -  Prostate seroma, prostate abscess, or urethral stenosis&#xD;
&#xD;
          -  An intraprostatic implant such as a stent or catheter, or any implant or prosthesis at&#xD;
             less than 1 cm from the prostate&#xD;
&#xD;
          -  Interest in future fertility&#xD;
&#xD;
          -  Concurrent illness, disability, or geographical residence would hamper attendance at&#xD;
             required study visits&#xD;
&#xD;
          -  Known latex hypersensitivity&#xD;
&#xD;
          -  Current participation in another clinical investigation of a medical device or a drug&#xD;
             or has participated in such a study within 30 days prior to study enrollment&#xD;
&#xD;
          -  The Investigator believes that the subject will be unwilling or unable to comply with&#xD;
             study protocol requirements, including the HIFU or cryotherapy procedure and&#xD;
             study-related follow up visit requirements.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carey Robertson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chinn &amp; Chinn Urology Associates</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univeristy of Colorado Hospital and Health Science Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Foundation for Healthcare Research Inc</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brooklyn Urology Research Group</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sloan-Kettering Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-2765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urolgoy Associates of North Texas</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Urology Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin, Inc.</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maple Leaf HIFU</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Th√ºroff S, Chaussy C, Vallancien G, Wieland W, Kiel HJ, Le Duc A, Desgrandchamps F, De La Rosette JJ, Gelet A. High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multicentric study. J Endourol. 2003 Oct;17(8):673-7.</citation>
    <PMID>14622488</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>February 22, 2006</study_first_submitted>
  <study_first_submitted_qc>February 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2006</study_first_posted>
  <last_update_submitted>February 6, 2014</last_update_submitted>
  <last_update_submitted_qc>February 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>HIFU</keyword>
  <keyword>EDAP</keyword>
  <keyword>Low Risk, Localized Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>July 20, 2018</submitted>
    <submission_canceled>July 20, 2018</submission_canceled>
    <submitted>July 30, 2019</submitted>
    <returned>August 21, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

